Last reviewed · How we verify
NCT04771975: C4E
Connecting Breast Cancer Survivors for Exercise
NA trial testing Exercise Counselling in Breast Cancer in 108 participants. Completed in 30 January 2022.
30 December 2021
Quick facts
| Lead sponsor | Jenna Smith |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 108 |
| Start date | 10 May 2021 |
| Primary completion | 30 December 2021 |
| Estimated completion | 30 January 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Exercise Counselling
- Partner Matching
- Resistance training sessions led by a QEP
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Breast Neoplasms — all drugs for Breast Neoplasms →
Sponsor
Jenna Smith
Who can join
18 and older, female only, with Breast Cancer or Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase 1: The purpose of this study is to examine interpersonal and individual effects of partnering BCS with a peer and a qualified exercise professional (QEP) on self-reported exercise volume (MVPA; primary outcome), and device-measured exercise volume (MVPA; Fitbit), social support, and HRQOL (secondary outcomes). Cost-effectiveness and intervention adherence will also be explored as tertiary outcomes. The effects of a peer and QEP-support intervention group, labelled MatchQEP, will be compared to a control group of BCS who are matched with a peer, but not a QEP, labelled Match. Phase 2: The purpose of this study is to examine whether the addition of 8-weekly QEP-lead resistance training Zoom sessions with an exercise partner interacts with social support (i.e., tangible, informational, emotional) and how this interaction relates to overall exercise volume as an extension of Phase 1 (one year after phase 1 was completed). A secondary aim of Phase 2 is to examine the direct influence of resistance training on body image, self-efficacy, the physical self, and body functionality among the participants.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Connecting breast cancer survivors for exercise: protocol for a two-arm randomized controlled trial.
Smith-Turchyn J, McCowan ME, O'Loughlin E, Fong AJ, et al · · 2021 · cited 8× · PMID 34649590 · DOI 10.1186/s13102-021-00341-w -
Connecting women who are diagnosed and treated for breast cancer to engage in physical activity: a two-arm randomized controlled trial.
Murray RM, O'Loughlin E, Smith-Turchyn J, Fong AJ, et al · · 2025 · cited 1× · PMID 40281585 · DOI 10.1186/s13102-025-01131-4 -
Resistance Training in Women Diagnosed with Breast Cancer: A Pilot Single Arm Pre-Post Intervention.
Vani MF, Marashi M, O'Loughlin EK, Smith-Turchyn J, et al · · 2024 · cited 1× · PMID 39199600 · DOI 10.3390/cancers16162829 -
Connecting breast cancer survivors for exercise: protocol for a two-arm randomized controlled trial.
Smith-Turchyn J, McCowan ME, O'Loughlin E, Fong AJ, et al · · 2021 · PMID 34664019 · DOI 10.1186/s13102-021-00341-w
Verify or expand the search:
- PubMed search for NCT04771975
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Exercise Counselling
Trials testing the same drug.
- NCT06624930 — Behaviour Change for Cancer Survivors Trial · NA · recruiting
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04771975 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jenna Smith
- Last refreshed: 21 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04771975.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing